The treatments for pituitary tumor generally include: surgery, gyroscopic knife radiation therapy, and drug therapy: 1. Surgery: Except for prolactinoma, which is generally treated with drug therapy first, all pituitary tumors, especially macroadenomas and functional tumors, especially compressing central nervous system and optic nerve bundles, and those who are ineffective in drug therapy or can not tolerate it, will consider surgical treatment. Unless the macroadenoma has been extended to the suprasellar and parasellar regions, craniotomy should be considered to remove the tumor via the frontal route, and transsphenoidal microsurgery is generally adopted to remove the microadenomas of intra-saddle tumors, with the surgical cure rate ranging from 70% to 80%, the recurrence rate ranging from 5% to 15%, and the postoperative complications, such as transient uremic collapse, cerebrospinal fluid leakage, local hematomas, abscesses, and the occurrence of infections, with the mortality rate being very low (<1%). Large adenomas, especially those tumors developing toward the suprasellar or parasellar region, have a lower surgical cure rate, an increase in postoperative complications, a higher incidence of urolithiasis and hypopituitarism, and a relatively higher mortality rate of up to 10%. 2, Gyro knife radiation therapy (recommended): Gyro knife is the most accurate and latest type of whole body stereotactic radiosurgery treatment equipment in the world. Only 3-5 times of irradiation can kill the tumor tissues in the pituitary gland, which is the only comprehensive "no wound, no pain, no blood, no anesthesia, short recovery period" and other advantages of the form of whole-body radiosurgery. 3.Drug therapy: With the long-term in-depth study of drug therapy, it is now known that prolactinoma can be treated with bromocriptine firstly, which can make the level of prolactin in the blood reduced to normal and the tumor shrunken, and the efficacy of the treatment is better than that of the surgery, but after stopping the drug, it can reproduce the hyperprolactinemia and the tumor enlarged, so it needs to be taken for a long period of time. Dopamine D2 agonist pergolide and cabergoline are also effective. Bromocriptine application so far has not found fetal malformations, so the effect on pregnancy is small, but for safety considerations, it is still advisable to stop the application during pregnancy. Growth hormone secretory tumors can be applied to octreotide, which can normalize plasma GH and insulin-like growth factor-l (IGF-1) in half of the patients. Octreotide is also indicated for TSH-secreting tumors, reducing serum TSH levels and shrinking tumors.